DAVENPORT & Co LLC Raises Stake in Kenvue Inc. (NYSE:KVUE)

DAVENPORT & Co LLC lifted its stake in shares of Kenvue Inc. (NYSE:KVUEFree Report) by 0.4% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 388,684 shares of the company’s stock after acquiring an additional 1,679 shares during the period. DAVENPORT & Co LLC’s holdings in Kenvue were worth $8,268,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Grove Bank & Trust raised its stake in Kenvue by 438.4% during the fourth quarter. Grove Bank & Trust now owns 1,163 shares of the company’s stock worth $25,000 after purchasing an additional 947 shares during the period. Geneos Wealth Management Inc. purchased a new stake in shares of Kenvue during the 4th quarter valued at approximately $29,000. Riverview Trust Co acquired a new position in Kenvue in the third quarter valued at approximately $30,000. Fortitude Family Office LLC grew its position in Kenvue by 106.6% in the fourth quarter. Fortitude Family Office LLC now owns 1,506 shares of the company’s stock worth $32,000 after acquiring an additional 777 shares during the period. Finally, Ashton Thomas Securities LLC acquired a new stake in Kenvue during the third quarter worth $35,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Trading Down 2.0 %

NYSE KVUE opened at $21.29 on Monday. Kenvue Inc. has a 52 week low of $17.67 and a 52 week high of $24.46. The firm has a 50 day moving average of $21.90 and a two-hundred day moving average of $21.92. The stock has a market capitalization of $40.82 billion, a PE ratio of 38.71, a price-to-earnings-growth ratio of 2.05 and a beta of 1.46. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66.

Kenvue (NYSE:KVUEGet Free Report) last posted its quarterly earnings results on Thursday, November 7th. The company reported $0.28 earnings per share for the quarter, beating analysts’ consensus estimates of $0.27 by $0.01. Kenvue had a return on equity of 21.43% and a net margin of 6.88%. The company had revenue of $3.90 billion for the quarter, compared to analysts’ expectations of $3.92 billion. During the same period last year, the firm earned $0.31 earnings per share. Kenvue’s quarterly revenue was down .4% on a year-over-year basis. As a group, research analysts expect that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, February 26th. Shareholders of record on Wednesday, February 12th will be issued a dividend of $0.205 per share. The ex-dividend date is Wednesday, February 12th. This represents a $0.82 dividend on an annualized basis and a yield of 3.85%. Kenvue’s payout ratio is currently 149.09%.

Analysts Set New Price Targets

KVUE has been the subject of a number of research analyst reports. Bank of America increased their price target on Kenvue from $24.00 to $27.00 and gave the stock a “buy” rating in a report on Tuesday, October 22nd. Citigroup dropped their price target on shares of Kenvue from $25.00 to $21.00 and set a “neutral” rating for the company in a research report on Wednesday, January 15th. JPMorgan Chase & Co. upped their price objective on shares of Kenvue from $24.00 to $25.00 and gave the stock an “overweight” rating in a report on Friday, October 11th. Royal Bank of Canada raised Kenvue from a “hold” rating to a “moderate buy” rating in a research report on Monday, December 9th. Finally, Barclays lowered their price target on Kenvue from $23.00 to $21.00 and set an “equal weight” rating for the company in a research report on Friday, January 17th. One research analyst has rated the stock with a sell rating, seven have given a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $23.08.

Get Our Latest Report on Kenvue

Kenvue Profile

(Free Report)

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.

Recommended Stories

Want to see what other hedge funds are holding KVUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kenvue Inc. (NYSE:KVUEFree Report).

Institutional Ownership by Quarter for Kenvue (NYSE:KVUE)

Receive News & Ratings for Kenvue Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kenvue and related companies with MarketBeat.com's FREE daily email newsletter.